Literature DB >> 23730320

Successful use of posaconazole to treat invasive cutaneous fungal infection in a liver transplant patient on sirolimus.

Randah Dahlan1, Ameen Patel, Shariq Haider.   

Abstract

Fungi are an important and common cause of cutaneous infections affecting solid organ transplant recipients. These infections can represent a primary site of infection with the potential for dissemination, or a manifestation of metastatic infection. The high morbidity and mortality associated with these infections necessitates urgent therapy with antifungal drugs; however, the interaction between these drugs and immunosuppressive therapies can be a major limitation because of drug toxicity. A case of soft tissue infection of the toe caused by Fusarium chlamydosporum and Candida guilliermondii in a liver transplant patient on sirolimus, who was successfully treated with the new antifungal agent posaconazole, is described. The pharmacokinetic interactions of sirolimus and the new triazoles, and their impact on treatment choices are briefly discussed.

Entities:  

Keywords:  Cutaneous fungal infections; Liver transplantation; Posaconazole; Sirolimus

Year:  2012        PMID: 23730320      PMCID: PMC3403665          DOI: 10.1155/2012/272197

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  17 in total

1.  Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.

Authors:  Francisco M Marty; Colleen M Lowry; Corey S Cutler; Bonnie J Campbell; Karen Fiumara; Lindsey R Baden; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2006-05       Impact factor: 5.742

Review 2.  Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.

Authors:  Aline H Saad; Daryl D DePestel; Peggy L Carver
Journal:  Pharmacotherapy       Date:  2006-12       Impact factor: 4.705

Review 3.  Invasive fungal infections: a review of epidemiology and management options.

Authors:  D A Enoch; H A Ludlam; N M Brown
Journal:  J Med Microbiol       Date:  2006-07       Impact factor: 2.472

4.  Clinical relevance of sirolimus drug interactions in transplant patients.

Authors:  B Sádaba; M A Campanero; E G Quetglas; J R Azanza
Journal:  Transplant Proc       Date:  2004-12       Impact factor: 1.066

5.  Cellulitis and nodular skin lesions due to Fusarium spp in liver transplant: case report.

Authors:  M Halpern; E Balbi; L Carius; J Roma; A C Gonzalez; L Agoglia; M Covelo; A Araujo; C Guedes; J Alves; M Enne; J M Martinho; L Pacheco
Journal:  Transplant Proc       Date:  2010-03       Impact factor: 1.066

Review 6.  New and emerging treatments for fungal infections.

Authors:  A C Pasqualotto; D W Denning
Journal:  J Antimicrob Chemother       Date:  2008-01       Impact factor: 5.790

7.  Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management.

Authors:  Dorothy Surowiec; Daryl D DePestel; Peggy L Carver
Journal:  Pharmacotherapy       Date:  2008-06       Impact factor: 4.705

Review 8.  Fusarium infections in immunocompromised patients.

Authors:  Marcio Nucci; Elias Anaissie
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

Review 9.  Fungal infections in solid-organ transplantation.

Authors:  C V Paya
Journal:  Clin Infect Dis       Date:  1993-05       Impact factor: 9.079

10.  Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus.

Authors:  Angela Sansone-Parsons; Gopal Krishna; Monika Martinho; Bhavna Kantesaria; Steven Gelone; Tim G Mant
Journal:  Pharmacotherapy       Date:  2007-06       Impact factor: 4.705

View more
  4 in total

Review 1.  Pharmacologic and clinical evaluation of posaconazole.

Authors:  Jason N Moore; Jason R Healy; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2015-05       Impact factor: 5.045

Review 2.  Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective.

Authors:  Michel Laverdiere; Eric J Bow; Coleman Rotstein; Julie Autmizguine; Raewyn Broady; Gary Garber; Shariq Haider; Trana Hussaini; Shahid Husain; Philippe Ovetchkine; Jack T Seki; Yves Théorêt
Journal:  Can J Infect Dis Med Microbiol       Date:  2014 Nov-Dec       Impact factor: 2.471

3.  A common mechanism involving the TORC1 pathway can lead to amphotericin B-persistence in biofilm and planktonic Saccharomyces cerevisiae populations.

Authors:  Rasmus Bojsen; Birgitte Regenberg; David Gresham; Anders Folkesson
Journal:  Sci Rep       Date:  2016-02-23       Impact factor: 4.379

4.  Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease.

Authors:  Xiao Chen; Jinglin Wang; Jianger Lan; Xilin Ge; Hong Xu; Yu Zhang; Zhiping Li
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.